- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Development of Siltuximab
Authors
Keywords
Siltuximab, Multicentric Castleman’s disease, Monoclonal antibody, Interleukin-6, Myeloma
Journal
Current Oncology Reports
Volume 17, Issue 7, Pages -
Publisher
Springer Nature
Online
2015-05-18
DOI
10.1007/s11912-015-0453-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Siltuximab: First Global Approval
- (2014) Anthony Markham et al. DRUGS
- Exploiting interleukin 6 in multicentric Castleman's disease
- (2014) Mark Bower et al. LANCET ONCOLOGY
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- Siltuximab for multicentric Castleman disease
- (2014) Yi-Chang Liu et al. Expert Review of Hematology
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
- (2013) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma
- (2013) Sheeba K. Thomas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
- (2013) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- Multicentric Castleman’s Disease: A Challenging Diagnosis
- (2013) Györgyi Műzes et al. PATHOLOGY & ONCOLOGY RESEARCH
- Surgery in Castlemanʼs Disease
- (2012) Nadia Talat et al. ANNALS OF SURGERY
- A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
- (2012) Gary Hudes et al. INVESTIGATIONAL NEW DRUGS
- Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
- (2011) H. E. El-Osta et al. ONCOLOGIST
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- (2010) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
- (2010) T. Puchalski et al. CLINICAL CANCER RESEARCH
- Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
- (2010) Frits van Rhee et al. JOURNAL OF CLINICAL ONCOLOGY
- Castleman Disease
- (2009) Danielle M. P. Cronin et al. ADVANCES IN ANATOMIC PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started